GF SEC (01776) will publicly issue subordinated bonds (second tranche) targeted at professional investors and list them on the Shenzhen Stock Exchange in 2026.
Guangfa Securities (01776) announced that, in accordance with the relevant regulations of the Shenzhen Stock Exchange for the listing of bonds, Guangfa Securities Co., Ltd. will publicly issue subordinated bonds (second tranche) for professional investors in 2026. This issuance meets the listing conditions of the Shenzhen Stock Exchange for bonds, and will be listed on the Shenzhen Stock Exchange starting from June 11, 2026. The trading will be open to professional institutional investors, and trading methods will include matched trading, click trading, inquiry trading, competitive bid trading, and negotiated trading. The bond details are as follows: bond abbreviation 26GuangfaC2, total issue amount of 1.67 billion yuan, bond term of 3 years, and a coupon rate of 1.70% per annum.
GF SEC (01776) announced that, in accordance with the relevant regulations of the Shenzhen Stock Exchange for the listing of bonds, GF SEC Limited will publicly issue subordinated bonds (second tranche) for professional investors in 2026. The bonds meet the listing conditions of the Shenzhen Stock Exchange and will be listed on June 11, 2026, and traded by professional institutional investors. The trading methods include matching trade, click trade, inquiry trade, competitive bidding trade, and negotiated trade. The bond details are as follows: bond abbreviation 26GFSEC C2, total issuance amount of 1.67 billion yuan, bond maturity of 3 years, and a face annual interest rate of 1.70%.
Related Articles
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
QINGSONG HEALTH (02661) signs a strategic cooperation memorandum with Basel Medical to achieve mutual development in technology output and technological iteration.
In the first five months of 02665, the total shipment of laser radar products was approximately 365,000 units, an increase of about 349% year-on-year, exceeding the total shipment of laser radar products for the entire year of 2025.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
QINGSONG HEALTH (02661) signs a strategic cooperation memorandum with Basel Medical to achieve mutual development in technology output and technological iteration.
In the first five months of 02665, the total shipment of laser radar products was approximately 365,000 units, an increase of about 349% year-on-year, exceeding the total shipment of laser radar products for the entire year of 2025.
RECOMMEND
